Document is current
Any future updates will be listed below
-
Authors
Adriaenssens, T.
Van Vaerenbergh, I.
Van Leuven, W.
Coucke, W.
Montenegro, S.
Zheng, W.
D’Hooghe, T.
Van Landuyt, L.
De Munck, N.
Van Hecke, E.
Smitz, J.
Rosenthal, A.
Blockeel, C.
- License Information
-
More Information
Article History
Received: 25 June 2025
Accepted: 7 October 2025
First Online: 22 November 2025
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki. Ethical approval was obtained from the Ethical Committee of Vrije Universiteit Brussel – UZ Brussel (IEC: 2020.335) and the study was registered at ClinicalTrials.gov (ID NCT04710264). The data were collected and analysed and the manuscript was prepared independently at Fertiga NV. All patients provided specific written informed consent prior to their fertility treatment at Universitair Ziekenhuis Brussel.
: Not applicable.
: IVV, TA and WVL report employment by Fertiga NV. JS is currently Chief Medical Officer, EVH is Chief Commercial Officer and AR is Chief Executive Officer at Fertiga NV. EVH, AR and JS report board membership of Fertiga NV, hold stock in Fertiga NV, and receive service fees from Fertiga NV. SM, WZ and TDH are employees of Merck Healthcare KGaA. Other authors declare no conflicts of interest associated with this work.
